* Atara Biotherapeutics Inc ATRA.OQ reported a quarterly
adjusted loss of $3.10 per share for the quarter ended in
June, higher than the same quarter last year, when the company
reported EPS of $-17.00. The mean expectation of five analysts
for the quarter was for a loss of $1.56 per share. Wall Street
expected results to range from $-4.50 to $1.50 per share.
* Revenue rose 2,892.7% to $28.64 million from a year ago;
analysts expected $39.99 million.
* Atara Biotherapeutics Inc's reported EPS for the quarter
was a
loss of $3.10.
* The company reported a quarterly loss of $19.05 million.
* Atara Biotherapeutics Inc shares had fallen by 10.8% this
quarter and lost 40.9% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 49% in
the last three months.
* In the last 30 days, one analyst negatively revised an
earnings
estimate
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is "hold."
Wall Street's median 12-month price target for Atara
Biotherapeutics Inc is $40.00
This summary was machine generated from LSEG data August 13 at
01:39 a.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -1.56 -3.10 Missed
Mar. 31 2024 -12.05 -5.75 Beat
Dec. 31 2023 -12.05 -14.00 Missed
Sep. 30 2023 -16.55 -16.50 Beat